Purpose: To compare the functional and morphological response to the initial intravitreal (IVT) injection of bevacizumab in exudative age-related macular degeneration (AMD) patients with the complement factor H (CFH) gene polymorphism T1277C in the Brazilian population. Methods: Twenty-five unrelated patients with treatment-naive exudative AMD underwent an IVT injection of 1.25 mg bevacizumab at the initial presentation (D0) and were reexamined 7 days (D7) and 28 days (D28) later. The time and extent of visual acuity (VA) and central retinal thickness (CRT) changes were evaluated according to the presence of the T1277C polymorphism. Results: In the homozygous risk group (CC), VA improvement was detected mostly from D7 to D28, while in the heterozygous (CT) and homozygous for the wild-type allele (TT) groups, functional response occurred earlier, from D0 to D7. Morphological response to the first IVT injection of bevacizumab was significant in the CT and TT groups, while the CC group presented no significant change in CRT up to D28. Conclusion: The CC variant of the CFH gene polymorphism T1277C is related to delayed functional and limited morphological response to the initial IVT injection of bevacizumab in exudative AMD patients in a sample of the Brazilian population.

Friedman DS, Katz J, Bressler NM, Rahmani B, Tielsch JM: Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey. Ophthalmology 1999;106:1049-1055.
IBGE: Instituto Brasileiro de Geografia e Estatística. Censo, 2010. Brasília, 2010. http://www.censo2010.ibge.gov.br (accessed February 14, 2015).
Bressler NM, Bressler SB, Fine SL: Age-related macular degeneration. Surv Ophthalmol 1988;32:375-413.
Brown DM, Regillo CD: Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 2007;144:627-637.
Hageman GS, Anderson DH, Johnson LV, et al: A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 2005;102:7227-7232.
Seddon JM, Francis PJ, George S, Schultz DW, Rosner B, Klein ML: Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration. JAMA 2007;297:1793-1800.
Augustin AJ, Kirchhof J: Inflammation and the pathogenesis of age-related macular degeneration. Expert Opin Ther Targets 2009;13:641-651.
Haines JL, Hauser MA, Schmidt S, et al: Complement factor H variant increases the risk of age-related macular degeneration. Science 2005;308:419-421.
Brantley MA Jr, Fang AM, King JM, Tewari A, Kymes SM, Shiels A: Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 2007;114:2168-2173.
Nischler C, Oberkofler H, Ortner C, et al: Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration. Acta Ophthalmol 2011;89:e344-e349.
Lee AY, Raya AK, Kymes SM, Shiels A, Brantley MA Jr: Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 2009;93:610-613.
Francis PJ: The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: the Lucentis Genotype Study (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2011;109:115-156.
Medina FM, Motta A, Takahashi WY, et al: Association of the Y402H polymorphism of CFH gene with response of exudative AMD to intravitreal VEGF inhibitors in the Brazilian population. Program No 2214 Annu Meet Assoc Res Vision Ophthalmol (ARVO), Orlando, May 2014.
Hagstrom SA, Ying GS, Pauer GJ, et al: Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology 2013;120:593-599.
Lazzeri S, Nardi M, Bocci G: Pharmacogenetic labyrinth of neovascular age-related macular degeneration therapy: how to escape and move forward? Pharmacogenomics 2013;14:1239-1242.
Gangnon RE, Lee KE, Klein BE, Iyengar SK, Sivakumaran TA, Klein R: Effect of the Y402H variant in the complement factor H gene on the incidence and progression of age-related macular degeneration: results from multistate models applied to the Beaver Dam Eye Study. Arch Ophthalmol 2012;130:1169-1176.
Djordjevic N, Carrillo JA, Ueda N, et al: N-Acetyltransferase-2 (NAT2) gene polymorphisms and enzyme activity in Serbs: unprecedented high prevalence of rapid acetylators in a White population. J Clin Pharmacol 2011;51:994-1003.
Hyman L, Neborsky R: Risk factors for age-related macular degeneration: an update. Curr Opin Ophthalmol 2002;13:171-175.
Kloeckener-Gruissem B, Barthelmes D, Labs S, et al: Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. Invest Ophthalmol Vis Sci 2011;52:4694-4702.
Skerka C, Lauer N, Weinberger AA, et al: Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration. Mol Immunol 2007;44:3398-3406.
Spaide RF, Laud K, Fine HF, et al: Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-390.
Bolz M, Simader C, Ritter M, et al: Morphological and functional analysis of the loading regimen with intravitreal ranibizumab in neovascular age-related macular degeneration. Br J Ophthalmol 2010;94:185-189.
Ferraz D, Bressanim G, Takahashi B, Pelayes D, Takahashi W: Three-monthly intravitreal bevacizumab injections for neovascular age-related macular degeneration: short-term visual acuity results. Eur J Ophthalmol 2010;20:740-744.
Silva AS, Teixeira AG, Bavia L, et al: Plasma levels of complement proteins from the alternative pathway in patients with age-related macular degeneration are independent of complement factor H Tyr402His polymorphism. Mol Vis 2012;18:2288-2299.
Tian J, Qin X, Fang K, et al: Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population. Pharmacogenomics 2012;13:779-787.
Orlin A HD, Chang W, Ho AC, Brown G, Kaiser RS, Regillo CD, Godshalk AN, Lier A, Kaderli B, Stambolian D: Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration. Retina 2012;32:4-9.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.